| Autor: |
Albarrán V; Medical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Villamayor ML; Medical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Pozas J; Medical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Chamorro J; Medical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Rosero DI; Medical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, Spain., San Román M; Medical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Guerrero P; Medical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Pérez de Aguado P; Medical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Calvo JC; Medical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, Spain., García de Quevedo C; Medical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, Spain., González C; Medical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, Spain., Vaz MÁ; Medical Oncology Department, Ramon y Cajal University Hospital, 28034 Madrid, Spain. |
| Abstrakt: |
There is substantial heterogeneity between different subtypes of sarcoma regarding their biological behavior and microenvironment, which impacts their responsiveness to immunotherapy. Alveolar soft-part sarcoma, synovial sarcoma and undifferentiated pleomorphic sarcoma show higher immunogenicity and better responses to checkpoint inhibitors. Combination strategies adding immunotherapy to chemotherapy and/or tyrosine-kinase inhibitors globally seem superior to single-agent schemes. Therapeutic vaccines and different forms of adoptive cell therapy, mainly engineered TCRs, CAR-T cells and TIL therapy, are emerging as new forms of immunotherapy for advanced solid tumors. Tumor lymphocytic infiltration and other prognostic and predictive biomarkers are under research. |
